Stocks & Investing
Stocks and Investing
Stocks and Investing 
Fri, November 18, 2011
TTP, AEGY, QING, CEHD, PSCC, POFCY, Removed From Naked Short Lists Today
November 18, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , announced today that these select companies have been After the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. TITAN PHARMA INC (AMEX:TTP), ALTERNATIVE ENERGY PARTNERS (OTC:AEGY), QINGDAO FOOTWEAR INC (OTC:QING), CHINA ELECTRONICS HOLDINGS (OTC:CEHD), (NASDAQ:PSCC), (OTC:POFCY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
TITAN PHARMA INC (AMEX:TTP) - Titan Pharmaceuticals, Inc. (Titan Pharmaceuticals), incorporated in February 1992, is a biopharmaceutical company that develops therapeutics for the treatment of central nervous system (CNS) disorders, cardiovascular disease, bone disease and other disorders. The Company focuses primarily on clinical development of products, such as Probuphine for the treatment of opioid dependence; Iloperidone for the treatment of schizophrenia and related psychotic disorders; Spheramine for the treatment of advanced Parkinson's disease; DITPA for the treatment of congestive heart failure and hyperlipidemia, and Gallium maltolate for the treatment of bone related diseases, chronic bacterial infections and cancer.
Probuphine
Probuphine is the first product to utilize the Company's novel, ProNeura long-term drug delivery technology. Probuphine is designed to provide six months of steady state therapeutic levels of buprenorphine, an approved agent for the treatment of opioid dependence and pain. In June 2004, Titan Pharmaceuticals announced final results from a pilot clinical study that evaluated the safety, pharmacokinetics and preliminary efficacy of Probuphine in the treatment of opioid-dependent patients. The Company is finalizing a clinical development plan with regulatory authorities in the United States and other countries to commence Phase III clinical testing, which, if successful, could potentially lead to product approval.
Iloperidone
Iloperidone has been evaluated in an extensive Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG. In June 2004, Titan Pharmaceuticals announced that Vanda Pharmaceuticals, Inc. acquired from Novartis Pharma AG the worldwide rights to develop and commercialize iloperidone. Vanda is pursuing completion of the iloperidone Phase III development program and initiated further Phase III clinical testing of iloperidone in November 2005. All of the Company's rights and economic interests in iloperidone, including royalties on sales of iloperidone, remain essentially unchanged under the agreement.
The Company competes with Janssen Pharmaceuticals, Eli Lilly, Novartis, AstraZeneca, Pfizer and Bristol-Myers Squibb.
Spheramine
Spheramine utilizes the Company's cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine is being studied in a multicenter, randomized, blinded, placebo controlled clinical trial in Parkinson's disease. This Phase IIb clinical study will enroll 68 patients with advanced Parkinson's disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety and tolerability of Spheramine.
Schering AG, the Company's corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. The Investigational New Drug application (IND) filed by Titan with the United States Food and Drug Administration (FDA) was transferred to Schering in November 2005.
DITPA
The Company's 3,5-diiodothyropropionic acid (DITPA) is an orally active analogue of thyroid hormone. The Company is evaluating DITPA as a potential treatment for congestive heart failure (CHF) associated with low-serum thyroid hormone (T3). DITPA is also being evaluated in a second randomized, double blind, placebo controlled Phase II study with NYHA Class II-IV CHF, sponsored by the Department of Veterans Affairs Cooperative Studies Program. Titan Pharmaceuticals is also developing DITPA as a potential treatment for hyperlipidemia. In March 2006, Titan Pharmaceuticals initiated a Phase II, randomized, double-blind, placebo-controlled study to evaluate DITPA in individuals receiving standard lipid-lowering therapy, whose LDL cholesterol levels are above National Cholesterol Education Program (NCEP) guidelines.
Gallium Maltolate
During the year ended December 31There is a failure to deliver in shares of TTP
ALTERNATIVE ENERGY PARTNERS (OTC:AEGY) - Alternative Energy Partners, Inc., a development stage company, focuses on providing commercial buildings with solar thermal energy production, allowing businesses to use alternative energy sources in the southern United States. Its products offer solar thermal heating and cooling. The company was founded in 2008 and is based in Fort Lauderdale, Florida. As of May 5, 2010, Alternative Energy Partners, Inc. operates as a subsidiary of Healthcare Of Today, Inc.There is a failure to deliver in shares of AEGY
QINGDAO FOOTWEAR INC (OTC:QING) - Qingdao Footwear, Inc. designs and retails branded footwear under the name in the Peoples Republic of China. It offers various mens and womens casual and business wear shoes. The company also markets its products through a distribution network of authorized independent distributors, as well as through third party retailers. As of March 31, 2010, it had 12 flagship stores, 11 exclusive third party managed retail outlets, and 192 outlets managed by distributors. Qingdao Footwear, Inc. was formerly known as Qingdao Hongguan Shoes Co., Ltd. and changed its name to Qingdao Footwear, Inc. in February 2010. The company was incorporated in 2003 and is headquartered in Qingdao, China.There is a failure to deliver in shares of QING
CHINA ELECTRONICS HOLDINGS (OTC:CEHD) - China Electronics Holdings, Inc. engages in the retail of consumer electronics and appliances in China. It primarily offers solar heaters, refrigerators, air conditioners, and televisions. The company was incorporated in 2007 and is based in China.There is a failure to deliver in shares of CEHD
(NASDAQ:PSCC) - There is a failure to deliver in shares of PSCC
(OTC:POFCY) - There is a failure to deliver in shares of POFCY
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO www.BUYINS.net (800) 715-9999 tom@buyins.net